A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer

You may be eligible if

• Patients are eligible for the study if they were 18 years of age or older at MBC diagnosis, had HR+/HER2- confirmed and initiated first line therapy (CDK4/6i, ET, CT, or other) in the metastatic setting during the period from February 2015 through June 2022 or data cutoff.